RBOT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RBOT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Debt-to-EBITDA measures a company's ability to pay off its debt.
Vicarious Surgical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.05 Mil. Vicarious Surgical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $13.79 Mil. Vicarious Surgical's annualized EBITDA for the quarter that ended in Dec. 2023 was $-50.26 Mil. Vicarious Surgical's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.30.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's
The historical rank and industry rank for Vicarious Surgical's Debt-to-EBITDA or its related term are showing as below:
During the past 4 years, the highest Debt-to-EBITDA Ratio of Vicarious Surgical was 2.43. The lowest was -0.21. And the median was -0.02.
The historical data trend for Vicarious Surgical's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vicarious Surgical Annual Data | |||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |
Debt-to-EBITDA | -0.01 | -0.04 | 2.43 | -0.21 |
For the Medical Devices subindustry, Vicarious Surgical's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Vicarious Surgical's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Vicarious Surgical's Debt-to-EBITDA falls into.
Debt-to-EBITDA measures a company's ability to pay off its debt.
Vicarious Surgical's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (1.047 | + | 13.785) | / | -69.192 | |
= | -0.21 |
Vicarious Surgical's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (1.047 | + | 13.785) | / | -50.256 | |
= | -0.30 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.
Vicarious Surgical (NYSE:RBOT) Debt-to-EBITDA Explanation
In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.
Be Aware
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's
Thank you for viewing the detailed overview of Vicarious Surgical's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
William John Kelly | officer: CFO and Treasurer | C/O VICARIOUS SURGICAL INC., 78 4TH AVENUE, WALTHAM MA 02451 |
Adam David Sachs | director, 10 percent owner, officer: President and CEO | C/O VICARIOUS SURGICAL INC., 78 4TH AVENUE, WALTHAM MA 02451 |
Sammy Khalifa | director, 10 percent owner, officer: Chief Technology Officer | C/O VICARIOUS SURGICAL INC., 78 4TH AVENUE, WALTHAM MA 02451 |
June Morris | officer: CLO, General Counsel and Sec | C/O VICARIOUS SURGICAL INC., 78 4TH AVENUE, WALTHAM MA 02451 |
John Mazzola | officer: Chief Operating Officer | TRANSMEDICS INC, 200 MINUTEMAN ROAD, ANDOVER MA 01810 |
Khosla Ventures Opportunity Associates Ii, Llc | 10 percent owner | 2128 SAND HILL ROAD, MENLO PARK CA 94025 |
Khosla Ventures V, L.p. | 10 percent owner | 2128 SAND HILL ROAD, MENLO PARK CA 94025 |
Khosla Ventures Opportunity Ii, L.p. | 10 percent owner | 2128 SAND HILL ROAD, MENLO PARK CA 94025 |
David D Ho | director | UNIT 1008, 10/F, CHAMPION TOWER, 3 GARDEN ROAD, CENTRAL K3 00000 |
Philip Liang | director | C/O VICARIOUS SURGICAL INC., 78 4TH AVENUE, WALTHAM MA 02451 |
Brendel Victoria Carr | director | C/O VICARIOUS SURGICAL, INC., 78 FOURTH AVENUE, WALTHAM MA 02451 |
Beverly A Huss | director | C/O ACCURAY INCORPORATED, 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089 |
E15 Fund Ii, Lp | other: Sole Shareholder | C/O VICARIOUS SURGICAL INC., 78 4TH AVENUE, WALTHAM MA 02451 |
Shrikant Patnaik | other: Principal | C/O VICARIOUS SURGICAL INC., 78 4TH AVENUE, WALTHAM MA 02451 |
Ric Fulop | director | C/O DESKTOP METAL, INC., 63 THIRD AVENUE, BURLINGTON MA 01803 |
From GuruFocus
By Business Wire 05-04-2023
By Business Wire 11-17-2022
By GuruFocus Editor 05-25-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.